IP Library Granted Patent US 8,598,215
Granted Patent B2
US 8,598,215 · App. 12/508,100 · Granted Dec 3, 2013

Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,215
App. No.
12/508,100
Granted
Dec 3, 2013
Kind
B2
Abstract

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

Claims (6)

1. A method for treating cancer selected from metastatic breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, colon cancer, and small cell lung cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula,

or a stereoisomer of Compound (1), and a dosage unit of bevacizumab, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or bevacizumab alone.

2. The method of claim 1 wherein the cancer is refractory, resistant, or sensitive to taxane treatment.

3. The method of claim 1 , wherein bevacizumab is administered following the administration of Compound (1).

4. The method according to claim 1 , wherein bevacizumab is administered before the administration of Compound (1).

5. The method according to claim 1 , wherein bevacizumab is administered substantially simultaneously with the administration of Compound (1).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2015
From: BRISTOL-MYERS SQUIBB COMPANY
To: R-PHARM US OPERATING LLC
Reel/Frame 036585/0956 →